and analysts at EvaluateVantage have suggested that CTX001 could become a $1.3 billion product if it gets approved for both indications. In October, CRISPR Therapeutics co-founder Emmanuelle ...

Development of a stem cell therapy for sickle cell disease from Vertex and development partner CRISPR therapeutics can ... to begin an early stage trial of CTX001, a gene therapy derived from ...